SCHEMBL6181029

SCHEMBL6181029

CC(C)(C)OC(=O)N1CCN(c2nc(CN3CCC(C(=O)O)CC3)cs2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.46
DNM1L O00429 1/20 0.43
ACKR3 P25106 3/20 0.42
F2RL3 Q96RI0 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
GBA1 P04062 1/20 0.39
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
GPR119 Q8TDV5 2/20 0.39
CHRM4 P08173 1/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
STS P08842 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
USP30 Q70CQ3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182617 0.90 HRH3 (0.45) HRH3ACKR3F2RL3GPR119CHRM4
SCHEMBL1118061 0.81 HRH3 (0.58) HRH3ACKR3F2RL3GBA1CKS1B
SCHEMBL17541493 0.81 HRH3 (0.49) HRH3ACKR3F2RL3GBA1CKS1B
SCHEMBL1118423 0.80 HRH3 (0.48) HRH3ACKR3F2RL3GBA1CKS1B
SCHEMBL6181625 0.78 ACKR3 (0.43) HRH3DNM1LACKR3CHRM4LMNA
SCHEMBL7542094 0.78 HRH3 (0.39) HRH3ACKR3F2RL3GPR119USP30
SCHEMBL6183507 0.78 CHRM4 (0.39) HRH3ACKR3F2RL3GPR119CHRM4
SCHEMBL6183501 0.77 HRH3 (0.38) HRH3ACKR3F2RL3GPR119CHRM4
SCHEMBL2734028 0.76 ALDH1A1 (0.60) ACKR3L3MBTL1CHRM4LMNAMAPT
SCHEMBL21579067 0.76 ACKR3 (0.49) ACKR3CHRM4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
CN-1362947-A N-cyanomethylamides as protease inhibitors AXYS PHARM INC (US) 2002-08-07 CN disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed
WO-2001068645-A2 N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 HRH3 2461/4885DNM1L 2641/4885ACKR3 3895/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 HRH3 2461/4885DNM1L 2641/4885ACKR3 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.